Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brain Dopaminergic Signaling in Opioid Use Disorders (OUD)
NCT03190954Phase 1Completed
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism
- Start
- Aug 2017
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-blind trial of methylphenidate hydrochloride extended-release chewable tablet (3 arms), sponsored by National Institute on Alcohol Abuse and Alcoholism. Primary endpoint: Differences in D1R to D2R striatal ratio and in DA release. Started Aug 2017; status: completed.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
Beyond the preview
Go deeper on NCT03190954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03190954.